Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/174259
Title: HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02)
Author: Mothe, Beatriz
Rosas-Umbert, Miriam
Coll, Pep
Manzardo, Christian
Puertas, Maria C.
Morón-López, Sara
Llano, Anuska
Miranda, Cristina
Cedeño, Samandhy
López, Miriam
Alarcón-Soto, Yovaninna
Gómez Melis, Gudalaupe
Langohr, Klaus
Barriocanal, Ana M.
Toro, Jessica
Ruiz, Irene
Rovira, Cristina
Carrillo, Antonio
Meulbroek, Michael
Crook, Alison
Wee, Edmund G.
Miró Meda, José M.
Clotet i Sala, Bonaventura
Valle, Marta
Martinez-Picado, Javier
Hanke, Tomás
Brander, Christian
Moltó, José
B.C.N02 Study Investigators
Keywords: VIH (Virus)
Vacunació
HIV (Viruses)
Vaccination
Issue Date: 6-May-2020
Publisher: Frontiers Media
Abstract: Kick&kill strategies combining drugs aiming to reactivate the viral reservoir with therapeutic vaccines to induce effective cytotoxic immune responses hold potential to achieve a functional cure for HIV-1 infection. Here, we report on an open-label, single-arm, phase I clinical trial, enrolling 15 early-treated HIV-1-infected individuals, testing the combination of the histone deacetylase inhibitor romidepsin as a latency-reversing agent and the MVA.HIVconsv vaccine. Romidepsin treatment resulted in increased histone acetylation, cell-associated HIV-1 RNA, and T-cell activation, which were associated with a marginally significant reduction of the viral reservoir. Vaccinations boosted robust and broad HIVconsv-specific T cells, which were strongly refocused toward conserved regions of the HIV-1 proteome. During a monitored ART interruption phase using plasma viral load over 2,000 copies/ml as a criterium for ART resumption, 23% of individuals showed sustained suppression of viremia up to 32 weeks without evidence for reseeding the viral reservoir. Results from this pilot study show that the combined kick&kill intervention was safe and suggest a role for this strategy in achieving an immune-driven durable viremic control.
Note: Reproducció del document publicat a: https://doi.org/10.3389/fimmu.2020.00823
It is part of: Frontiers in Immunology, 2020, vol. 11, num. 823
URI: http://hdl.handle.net/2445/174259
Related resource: https://doi.org/10.3389/fimmu.2020.00823
ISSN: 1664-3224
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
701544.pdf3.43 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons